Frank G. Haluska

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

Medicine, Oncology, Pharmacology +16

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

F. Stephen Hodi, Martín C. Mihm, Robert J. Soiffer et al. · Proceedings of the National Academy of Sciences · 2003 · 997 citations · Full text

Life Sciences, Immunology, Oncology +17

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, Hagop M. Kantarjian, Neil P. Shah et al. · New England Journal of Medicine · 2012 · 770 citations · Full text

Medicine, Oncology, Pharmacology +13

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

F. Stephen Hodi, Marcus O. Butler, Darryl A. Oble et al. · Proceedings of the National Academy of Sciences · 2008 · 648 citations · Full text

Medicine, Immunology, Oncology +17